Peter Fedichev Says Three Variables May Explain How and Why We Age

Aging research is often framed around a growing list of hallmarks — senescence, telomere shortening, mitochondrial dysfunction, and more. But physicist and Gero co-founder Peter Fedichev argues this complexity may be unnecessary. In a conversation with Eleanor Sheekey, he proposes that aging can be modeled using just three variables: stress, damage, and noise. This reductionist framework, grounded in physics and systems biology, may offer a cleaner lens for predicting how organisms age and which interventions are most likely to matter.

A central claim in the discussion is that most current longevity interventions — including many celebrated in the field — are 'level 1' therapies. They reduce accumulated damage or physiological stress, but they do not address the underlying dynamical instability that Fedichev believes drives aging at a deeper level. True 'level 2' interventions would need to reduce physiological noise itself, a concept he links to 'effective temperature,' borrowing language from statistical physics to describe how erratically biological systems behave over time.

Fedichev also draws a sharp distinction between mice and humans as aging systems. Mice, he suggests, are 'unstable' species whose aging is driven differently than in long-lived humans. This has major implications for translational research — interventions that extend mouse lifespan may not work by the same mechanisms in humans, and the field may be systematically misled by over-relying on rodent models.

The episode also tackles whether tissue replacement strategies — regenerative medicine approaches — can genuinely reverse aging or simply delay it, and how AI-driven drug discovery might accelerate progress toward therapies that target the root physics of aging.

For health-conscious individuals, the key implication is sobering but clarifying: many popular longevity supplements and lifestyle interventions may offer real but limited benefits. Achieving meaningful lifespan extension beyond current apparent limits may require a fundamentally different class of therapy still in early development.